Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.56 |
| ▸ | CTSL | P07711 | 6/20 | 0.56 |
| ▸ | CTSV | O60911 | 4/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452807 | 0.92 | CTSS (0.57) | CTSSCTSLCTSVCTSKKMT2A | |
| SCHEMBL4446408 | 0.92 | CTSK (0.57) | CTSSCTSLCTSVCTSKHPGDS | |
| SCHEMBL4454295 | 0.92 | CTSS (0.64) | CTSSCTSLCTSVCTSKKMT2A | |
| SCHEMBL6801627 | 0.91 | CTSS (0.67) | CTSSCTSLCTSVCTSKHPGDS | |
| SCHEMBL4455907 | 0.91 | CTSS (0.59) | CTSSCTSLCTSVCTSKKMT2A | |
| SCHEMBL4457983 | 0.88 | CTSS (0.55) | CTSSCTSLCTSVCTSKKMT2A | |
| SCHEMBL4456326 | 0.88 | CTSS (0.56) | CTSSCTSLCTSVCTSKKMT2A | |
| SCHEMBL4449224 | 0.88 | CTSS (0.56) | CTSSCTSLCTSVCTSKKMT2A | |
| SCHEMBL4458880 | 0.88 | CTSS (0.56) | CTSSCTSLCTSVCTSKKMT2A | |
| SCHEMBL4457957 | 0.88 | CTSS (0.56) | CTSSCTSLCTSVCTSKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
| US-7425562-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD. (GB) | 2008-09-16 | — | — | US | disclosed |
| EP-1362052-B1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSS 39/4885CTSL 23/4885CTSV 27/4885 |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | CTSS 21/4885CTSL 16/4885CTSV 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.